Tag: Survival
Prognostic Factors ID’d for Stage IIIb AL Amyloidosis
Symptom onset to diagnosis longer than six months, bone marrow plasmacytosis ≥10 percent associated with shorter overall survival
Nivolumab + Ipilimumab Tops Ipilimumab Alone in Metastatic Melanoma
Significant improvement seen in progression-free survival for combination of nivolumab and ipilimumab
Lorazepam Has Negative Impact on Survival in Pancreatic Cancer
Alprazolam reduced IL-6 in human pancreatic cancer-associated fibroblasts and was associated with improved progression-free survival
Time to Treatment Not Tied to Worse Outcomes in Young Colorectal Cancer Patients
Findings seen for both overall survival and cause-specific survival
Living in Disadvantaged Neighborhood Shortens Breast Cancer Survival
Findings seen after adjusting for sociodemographics, comorbidity, breast cancer risk factor, access to care, tumor, and guideline-concordant treatment
Adding Pembrolizumab to Chemo Improves Survival in Endometrial Cancer
Addition of pembrolizumab to paclitaxel plus carboplatin yields longer progression-free survival in advanced, recurrent disease
Adding Dostarlimab Improves Progression-Free Survival in Endometrial Cancer
Dostarlimab plus carboplatin-paclitaxel linked to increased progression-free survival overall and in dMMR-MSI-H population
Frequent Social Activity Tied to Longer Survival in Older Adults
Threshold effect seen with meaningful benefit for participating in social activity almost every day
Survival Rate Lower for Surgery Nine Weeks or More After Breast Cancer Diagnosis
Younger age, uninsured or Medicaid status, and lower household income were associated with longer times to surgery
SBRT Well Tolerated, Effective for Primary Lung Neuroendocrine Tumor
At three, six, and nine years, overall survival was 64, 43, and 26 percent and progression-free survival was 88, 78, and 78 percent, respectively
